Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy

Neurology

Volumn 67, Issue 3, 2006, Pages 400-406

  Blum, D ^a   Meador, K ^b   Biton, V ^c   Fakhoury, T ^d   Shneker, B ^e   Chung, S ^f   Mills, K ^g   Hammer, A ^a   Isojarvi J ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Arkansas Epilepsy Program   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f BARROW NEUROLOGICAL INSTITUTE   (United States)

^g Profile Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; TOPIRAMATE;

ADULT; AMNESIA; ANXIETY DISORDER; APHASIA; ARTICLE; ATTENTION DISTURBANCE; BLUNTED AFFECT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; HYPESTHESIA; LEARNING; MALE; MEMORY DISORDER; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; RHINOPHARYNGITIS; SIDE EFFECT; SIMULATION; SINUSITIS; SOMNOLENCE; SPEECH DISORDER; STANDARDIZATION; TASK PERFORMANCE; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; COGNITION; DOUBLE-BLIND METHOD; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZINES;

EID: 33747068234     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000232737.72555.06     Document Type: Article

References (37)

1. Smith DB, Craft BR, Collins J, Mattson RH, Cramer JA, VA Cooperative Study Group 118. Behavioral characteristics of epilepsy patients compared with normal controls. Epilepsia 1986;27:760-768.
2. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003;44 (suppl 4):21-29.
3. Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy. Drugs 2002;62:593-604.
4. Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003;4 (suppl 2):S25-S38.
5. Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. Epilepsy Behav 2004;5 (suppl 1):S60-S65.
6. Trimble MR. Quality of life and cognitive function. In: Trimble MR, Dodson WE, eds. Epilepsy and quality of life. New York: Raven Press, 1994:183-197.
7. Giovagnoli AR, Avanzini G. Quality of life and memory performance in patients with temporal lobe epilepsy. Acta Neurol Scand 2000;101:295-300.
8. Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001; 2:85-91.
9. Kockelmann E, Elger CE, Helmstaedter C. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav 2004;5:716-721.
10. Goldberg JF, Burdick KE. Cognitive side effects of anticonvulsants. J Clin Psychiatry 2001;62 (suppl 14):27-33.
11. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52:321-327.
12. Aldenkamp AP, Mulder OG, Overweg J. Cognitive effects of lamotrigine as first-line add-on in subjects with localization-related (partial) epilepsy. J Epilepsy 1997;10:117-121.
13. Placidi F, Marciani MG, Diomedi M, et al. Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive function in focal epilepsy. Acta Neurol Scand 2000;102:81-86.
14. Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6:373-381.
15. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69: 636-641.
16. Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42:1134-1140.
17. Huppertz HJ, Quiske A, Schulze-Bonhage A. Cognitive impairment in add-on therapy with topiramate. Nervenarzt 2001;72:275-280.
18. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in subjects with partial-onset seizures. Epilepsia 2000;41:1167-1178.
19. Ojemann LM, Ojemann GA, Dodrill CB, Crawford CA, Holmes MD, Dudley DL. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav 2001;2:579-584.
20. Salinsky MC, Storzbach D, Spencer DC, Oken BS, Landry T, Dodrill CB. Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 2005;64:792-798.
21. Salinsky MC, Binder LM, Oken BS, Storzbach D, Aron CR, Dodrill CB. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia 2002;43:482-490.
22. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003;13;60:1483-1488.
23. Meador KJ, Loring DW, Vahle VJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005;64:2108-2115.
24. Loonstra AS, Tarlow AR, Sellers AH. COWAT metanorms across age, education, and gender. Appl Neuropsychol 2001;8:161-166.
25. Jensen AR, Rohwer WD Jr. The Stroop Color-Word Test: a review. Acta Psychologica 1966;25:36-93.
26. Mungas D. Differential clinical sensitivity of specific parameters of the Rey Auditory Verbal Learning Test. J Consult Clin Psychol 1983;51:848-855.
27. Sheridan LK, Fitzgerald HE, Adams KM, et al. Normative Symbol Digit Modalities Test performance in a community-based sample. Arch Clin Neuropsychol 2005;Aug 30 [Epub ahead of print].
28. Brooks J, Baker GA, Aldenkamp AP. The A-B neuropsychological assessment schedule: the further refinement of a subject-based scale of subject-perceived cognitive functioning. Epilepsy Res 2001;43:227-237.
29. Mills KC, Parkman KM, Spruill SE. A PC-based software test for measuring alcohol and drug effects in human subjects. Alcohol Clin Exp Res 1996;20:1582-1591.
30. Mills KC, Parkman KM, Smith GA, et al. Prediction of driving performance through computerized testing: high-risk driver assessment and training. Transportation Research Record 1999;1689:18-24.
31. Mills KC, Spruill SE, Kanne RW, et al. The influence of stimulants, sedatives, and fatigue on tunnel vision: risk factors for driving and piloting. Human Factors 2001;43:310-327.
32. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-1087.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc 1995;B57:289.
34. Juniper EF, Guyatt GH, Willan A. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-87.
35. Topamax (topiramate) complete prescribing information. Titusville, NJ: Ortho-McNeil Neurologics Inc., June 2005.
36. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-1025.
37. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-2291.